PDF(Pubmed)
Abstract：
UNASSIGNED: Olfactory neuroblastoma (ONB) is a rare malignant tumor arising from the olfactory neuroepithelium. The standard of care for ONB is surgical resection; however, detailed treatment protocols vary by institution. Our treatment protocol consists of endoscopic skull base surgery (ESBS) for endoscopically resectable cases and induction chemotherapy followed by craniotomy combined with ESBS for locally advanced cases, with postoperative radiotherapy performed for all cases. Chemoradiotherapy (CRT) is performed in unresectable cases. In this study, we evaluate our treatment protocol and outcomes for ONB.
UNASSIGNED: A retrospective review of patients with ONB was conducted. Outcomes included survival outcomes and perioperative data.
UNASSIGNED: Fifteen patients (53.6%) underwent ESBS, 12 (42.9%) underwent craniotomy combined with ESBS, and 1 (3.6%) received CRT. The 5- and 10-year overall survival rates for all patients were 92.9% and 82.5%, respectively, with a median follow-up period of 81 months. The 5- and 10-year disease-free survival rates were 77.3% and 70.3%, respectively, and the 5- and 10-year local control rates were 88.2% and 80.2%, respectively. Patients undergoing ESBS demonstrated a significantly shorter operating time, period from operation to ambulation, hospitalization period, and less blood loss than those undergoing craniotomy combined with ESBS.
UNASSIGNED: Our treatment protocol was found to afford favorable outcomes. Patients who underwent endoscopic resection showed lower complication rates and better perioperative data than those who underwent craniotomy combined with ESBS. With appropriate case selection, ESBS is considered a useful approach for ONB.
UNASSIGNED: A retrospective review of patients with ONB was conducted. Outcomes included survival outcomes and perioperative data.
UNASSIGNED: Fifteen patients (53.6%) underwent ESBS, 12 (42.9%) underwent craniotomy combined with ESBS, and 1 (3.6%) received CRT. The 5- and 10-year overall survival rates for all patients were 92.9% and 82.5%, respectively, with a median follow-up period of 81 months. The 5- and 10-year disease-free survival rates were 77.3% and 70.3%, respectively, and the 5- and 10-year local control rates were 88.2% and 80.2%, respectively. Patients undergoing ESBS demonstrated a significantly shorter operating time, period from operation to ambulation, hospitalization period, and less blood loss than those undergoing craniotomy combined with ESBS.
UNASSIGNED: Our treatment protocol was found to afford favorable outcomes. Patients who underwent endoscopic resection showed lower complication rates and better perioperative data than those who underwent craniotomy combined with ESBS. With appropriate case selection, ESBS is considered a useful approach for ONB.
摘要：
■嗅觉神经母细胞瘤（ONB）是一种罕见的由嗅觉神经上皮引起的恶性肿瘤。ONB的护理标准是手术切除；然而，详细的治疗方案因机构而异。我们的治疗方案包括内窥镜颅底手术（ESBS），用于内窥镜可切除的病例，以及诱导化疗，然后开颅手术联合ESBS用于局部晚期病例。对所有病例进行术后放疗。在无法切除的病例中进行放化疗（CRT）。在这项研究中,我们评估ONB的治疗方案和结果。
■对ONB患者进行回顾性分析。结果包括生存结果和围手术期数据。
■15名患者（53.6%）接受了ESBS，12例（42.9%）接受开颅手术联合ESBS，1人(3.6%)接受CRT治疗。所有患者的5年和10年总生存率分别为92.9%和82.5%,分别,中位随访期为81个月。5年和10年无病生存率分别为77.3%和70.3%,分别,5年和10年局部控制率分别为88.2%和80.2%,分别。接受ESBS的患者手术时间明显缩短，从操作到步行的时间，住院期间，与开颅手术联合ESBS的患者相比，失血更少。
■我们的治疗方案被发现提供了良好的结果。与接受开颅手术联合ESBS的患者相比，接受内镜切除术的患者显示出更低的并发症发生率和更好的围手术期数据。通过适当的案例选择，ESBS被认为是ONB的有用方法。
■对ONB患者进行回顾性分析。结果包括生存结果和围手术期数据。
■15名患者（53.6%）接受了ESBS，12例（42.9%）接受开颅手术联合ESBS，1人(3.6%)接受CRT治疗。所有患者的5年和10年总生存率分别为92.9%和82.5%,分别,中位随访期为81个月。5年和10年无病生存率分别为77.3%和70.3%,分别,5年和10年局部控制率分别为88.2%和80.2%,分别。接受ESBS的患者手术时间明显缩短，从操作到步行的时间，住院期间，与开颅手术联合ESBS的患者相比，失血更少。
■我们的治疗方案被发现提供了良好的结果。与接受开颅手术联合ESBS的患者相比，接受内镜切除术的患者显示出更低的并发症发生率和更好的围手术期数据。通过适当的案例选择，ESBS被认为是ONB的有用方法。
